CPRX - カタリスト・ファ―マシュ―ティカルズ (Catalyst Pharmaceuticals Inc.) カタリスト・ファ―マシュ―ティカルズ

 CPRXのチャート


 CPRXの企業情報

symbol CPRx
会社名 Catalyst Pharmaceuticals Inc (カタリスト・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 カタリスト・ファーマシューティカル(Catalyst Pharmaceuticals Inc. )(旧名:Catalyst Pharmaceutical Partners Inc.)は、開発段階のバイオ医薬品会社である。同社は、希少な衰弱性疾患を患うの人々のための治療法の開発及び商品化に注力する。同社には、「Firdapse」、「CPP-109」及び「CPP-115」の3品目の開発中の薬剤がある。「Firdapse」は、ランバート摂食筋萎縮症候群(LEMS)及び先天性筋無力症候群(CMS)の治療に適応され、amifampridineのリン酸塩から構成される。「Firdapse」の第Ⅲ相試験は完了した。「CPP-109」は、γ-アミノ酪酸(GABA)アミノトランスフェラーゼ阻害剤であり、トゥレット症候群の治療に適応される。「CPP-115」は、GABAアミノトランスフェラーゼ阻害剤であり、複雑な部分発作、トゥレット症候群及びてんかん発作などの神経学的適応症の治療に適応される。   カタリスト・ファ―マシュ―ティカルズは米国の医薬品メ―カ―。神経筋と神経疾患をタ―ゲットとして処方薬の開発と商業化に従事。筋力低下を特徴とする自己免疫疾患であるランバ―ト・イ―トン症候群の治療薬Firdapse、乳児けいれんの治療薬CPP-115、トゥレット症候群治療CPP-109の開発を行う。本社はフロリダ州。   Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
本社所在地 355 Alhambra Circle Suite 1250 Coral Gables FL 33134 USA
代表者氏名 Patrick James McEnany パトリック・ジェームス・マッケナニー
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 305-529-2522
設立年月日 38899
市場名 NASDAQ Small Cap
ipoyear 2006年
従業員数 21人
url www.catalystpharma.com
nasdaq_url https://www.nasdaq.com/symbol/cprx
adr_tso
EBITDA EBITDA(百万ドル) -22.05182
終値(lastsale) 3.39
時価総額(marketcap) 347811484.62
時価総額 時価総額(百万ドル) 339.60350
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 271.19460
当期純利益 当期純利益(百万ドル) -21.23038
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Catalyst Pharmaceuticals Inc revenues was not reported. Net loss increased 32% to $11.7M. Higher net loss reflects reasear increase of 32% to $6.4M (expense) General and administrative - Balancing increase of 57% to $4.1M (expense) Stock-based Compensation in SGA increase of 23% to $1.2M (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.11.

 CPRXのテクニカル分析


 CPRXのニュース

   Catalyst (CPRX) Up 52.1% Since Last Earnings Report: Can It Continue?  2020/04/15 15:30:11 Zacks Investment Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   Catalyst's (CPRX) Q4 Earnings Miss Estimates, Revenues Meet  2020/03/17 10:35:00 Zacks Investment Research
Catalyst's (CPRX) earnings lag estimates in the fourth quarter. Revenues match the same.
   Catalyst Gives Preliminary Firdapse Estimates & Other Updates  2020/01/07 08:17:00 Zacks Investment Research
Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.
   Why Is Catalyst (CPRX) Down 5.3% Since Last Earnings Report?  2019/12/12 16:30:19 Zacks Investment Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Why Is Catalyst (CPRX) Down 5.3% Since Last Earnings Report?  2019/12/12 16:30:19 Zacks Investment Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Catalyst Focuses on Firdapse Label Expansion Amid Competition  2019/11/29 08:39:00 Zacks Investment Research
Catalyst (CPRX) focuses on the development of Firdapse for additional indications.
   Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store?  2019/10/29 08:46:00 Zacks Investment Research
During Catalyst's (CPRX) third-quarter 2019 conference call, investor focus will be on the sales performance of its only marketed drug Firdapse and its label expansion studies.
   Catalyst Pharmaceutical (CPRX) is a Great Momentum Stock: Should You Buy?  2019/09/13 14:00:06 Zacks Investment Research
Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
   Implied Volatility Surging for Catalyst (CPRX) Stock Options  2019/09/13 12:41:00 Zacks Investment Research
Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.
   Catalyst Pharma +3.4% as director buys 20,000 shares  2018-12-14
Catalyst Pharmaceuticals (NASDAQ: CPRX ) is up 3.4% postmarket, after the disclosure that director Charles O'Keeffe bought 20,000 shares today. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カタリスト・ファ―マシュ―ティカルズ CPRX Catalyst Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)